Skip to main content

Table 1 Clinical characteristics of the analyzed samples

From: Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors

Clinicopathological factor N(%)
Tumorsize  
T0 26(11%)
T1 67(28.3%)
T2 35(14.8%)
T3 64(27%)
T4 45(18.9%)
Unknown 1
Stage  
DCIS 26(11.5%)
I 65(28.9%)
II 20(8.9%)
III 92(40.9%)
IV 22(9.8%)
Unknown 13
Lymphnode status  
N0 114(50.7%)
N1 76(34.9%)
N2 32(14.4%)
Unknown 16
Grade  
G1 42(17.7%)
G2 128(54%)
G3 67(28.3%)
Unknown 1
HER2 status  
Negative 60(57.1%)
Positive 45(42.9%)
Unknown 133
Progesteron receptor  
Negative 69(29.2%)
Positive 167(70.8%)
Unknown 2
Estrogene receptor  
Negative 53(22.7%)
Positive 180(77.3%)
Unknown 5
TP53 mutation  
Wild type 174(73.4%)
Mutated 63(26.6%)
Unknown 1
Distant metastasis  
No distant metastasis 214(90.3%)
Distant metastasis 23(9.7%)
Unknown 1
Molecular subtypes  
Luminal A 52(30.8%)
Luminal B 34(20.1%)
ERRB2 29(17.2%)
Basal 37(21.9%)
Normal 17(10%)
Unknown 69
  1. Unknown data was excluded from total when the percentage was calculated.